Quarterly ResultAug 7, 2026, 04:13 PM
Ligand Pharma Q2 Net Income $48.5M, EPS $2.42; Revenue $63.7M
AI Summary
Ligand Pharmaceuticals reported strong financial results for Q2 2026, with net income soaring to $48.5 million, a 900% increase year-over-year, and basic EPS reaching $2.42. Total revenues and income grew 33.7% to $63.7 million. The company also significantly improved its cash position, with cash and cash equivalents reaching over $1 billion, partly due to the issuance of $700 million in Convertible Senior Notes. Additionally, Ligand repurchased $60 million of common stock.
Key Highlights
- Q2 2026 net income surged to $48.5 million, up 900% year-over-year.
- Basic EPS for Q2 2026 was $2.42, a significant increase from $0.25 in Q2 2025.
- Total revenues and income for Q2 2026 rose 33.7% to $63.7 million.
- Year-to-date net cash provided by operating activities was $72.7 million, reversing a prior loss.
- Cash and cash equivalents reached $1.01 billion at June 30, 2026, up 475% from Dec 2025.
- The company issued $700 million in Convertible Senior Notes.
- Common stock repurchases totaled $60 million during the period.
- Revenue from intangible royalty assets increased 24.2% year-to-date to $70.3 million.
Price Impact
More from LGND